



Ocean-powered ingredients
to regenerate the planet.



Disclaimer

Don't invest unless you are prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong.

Deep Blue Biotech

PRESENTATION DISCLAIMER

This presentation (“**Presentation**”) is being provided to you (the “**Recipient**”) by [Company name] Limited (the “**Company**”) for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company.

The content of this Presentation has not been approved by an authorised person for the purposes of Section 21(2)(b) of the Financial Services and Markets Act 2000. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

This Presentation is not a prospectus or an admission document or an advertisement and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any ordinary shares of the Company (“**Shares**”) in the United States or any other jurisdiction where the sale of Shares is restricted or prohibited. Neither the Presentation, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any Shares.

The contents of this Presentation have not been approved by an authorised person in accordance with section 21 of FSMA and therefore it is being delivered to a very limited number of persons and companies who are (i) if outside the United Kingdom or outside a member state of the European Economic Area, persons to whom the communication may be lawfully made; or (ii) if in a member state of the European Economic Area, persons who are qualified investors, being person falling within the meaning of Article 2(e) of Prospectus Regulation (EU) 2017/1129 (as amended from time to time); or (iii) if in the United Kingdom, persons who are qualified investors, being persons falling within the meaning of Article 2(e) of Prospectus Regulation (EU) 2017/1129 (as amended from time to time) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, and who are (a) persons having professional experience in matters relating to investments who fall within the definition "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order, or (c) certified high net worth individuals within the meaning of Article 48 of the Order, sophisticated investors within the meaning of Article 50 of the Order or self-certified sophisticated investors within the meaning of Article 50A of the Order and any other persons who fall within other applicable exemptions under the Order, or (d) persons to whom the communication may otherwise lawfully be made (together, "**Relevant Persons**"). Any investment or investment activity to which this Presentation relates is available only to, and will be engaged in only with, Relevant Persons. This Presentation must not be acted on or relied on by persons who are not Relevant Persons. This Presentation is only being sent to persons reasonably believed by the Company to be Relevant Persons. If you are not a Relevant Person (i) you should not have received this Presentation and (ii) please return this Presentation to the Company's registered office as soon as possible and take no other action. By accepting this Presentation, you represent and warrant to the Company that you are a Relevant Person entitled to receive this Presentation.

This Presentation contains highly confidential information regarding the company. Your acceptance of the Presentation constitutes your agreement to (i) keep confidential all the information contained herein, as well as any information derived by you from the information contained herein (collectively “**Confidential Information**”) and not disclose any such Confidential Information to any other person, (ii) not use any of the Confidential Information for any purpose other than to evaluate your investment in the Company, (iii) not copy this document without the Company's prior consent, and (iv) promptly return this document and any copies hereof to the Company upon the Company's request.

The Company is not responsible to the Recipient for providing regulatory and legal protections afforded to customers (as defined in the rules of the Financial Conduct Authority) nor for providing advice in relation to the contents of this Presentation on any matter, transaction or arrangement referred to in it. Neither of the Company, it affiliates nor any of their respective directors, officers or employees makes any representation or warranty, express or implied, as to the accuracy or completeness of the information or opinions contained in this Presentation. To the fullest extent permitted by law, neither the Company, its affiliates nor any of their respective members, directors, officers, employees, agents or representatives nor any other person accepts any liability whatsoever for any errors, omissions, inaccuracies or misstatements (negligent or otherwise) in such information or opinions contained in this Presentation or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this Presentation or its contents or otherwise in connection with the subject matter of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice.

Nothing in this Presentation is, or should be relied on as, a promise or representation as to the future. This Presentation contains forward-looking statements. All statements other than statements of historical facts included herein, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's business) are forward-looking statements. These forward-looking statements are identified by the use of words such as “believe”, “expect”, “potential”, “continue”, “may”, “will”, “should”, “seek”, “approximately”, “predict”, “intend”, “plan”, “estimate”, “anticipate” or other comparable words. These forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Should any assumptions underlying the forward-looking statements contained in this Presentation prove to be incorrect, the actual outcome or results may differ materially from outcomes or results projected in these statements. The Company is under no obligation to update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law or regulation.

Recipients of the Presentation outside the United Kingdom should inform themselves about and observe any applicable legal restrictions in their jurisdiction which may be relevant to the distribution, possession or use of the Presentation and recognise that the Company does not accept any responsibility for contravention of any legal restrictions in such jurisdiction. In particular, neither the Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any person in Australia, Canada, Japan, the Republic of South Africa (“**South Africa**”) or the United States of America where it would be unlawful to do so. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (“**Securities Act**”), or under the securities legislation of any state of the United States nor under the relevant securities laws of Australia, Canada, Japan or South Africa and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.

THE PROBLEM

Green chemicals are vital for a net-zero future, but their first generation failed in the market

8% of global CO₂ emissions

Green chemicals represent only **2%** of market value



Green premiums




Inferior products



OUR SOLUTION

Cyanobacteria



- Most effective photosynthetic organism

- Can be genetically engineered

- Cleanest technology for manufacturing


TECHNOLOGY PLATFORM

Commercially viable photosynthetic manufacturing

Computational
Modelling



High performing
strain engineering




Low CAPEX scale-up &
Integrated downstream




PRODUCT DEVELOPMENT PROCESS

Targeting the right products



Ideal products



Value Proposition & Opportunity

Ocean derived BLUE Hyaluronic Acid



\$15B TAM

\$9B SAM

Skin Care & Hair Care

All Hyaluronic Acid, including
Health & Wellbeing uses

 **8% CAGR**


DBB PRODUCT ADVANTAGES

- Less Expensive
- Unique product claims.

Unit Economics

DBB Blue Hyaluronic Acid is cost-competitive and profitable

Current Hyaluronic Acid Market Prices vs DBB



DBB Hyaluronic Acid priced at **\$1750/kg**:

- ☐ **65% Gross Profit**
- ☐ **40% cheaper than incumbents**

Impact

CO₂ as the feedstock gives Cyanobacteria an edge

BLUE HYALURONIC ACID vs ALTERNATIVES





Givaudan



kewpie


Feedstock Availability

We use CO₂ instead of sugar



More Energy Efficient

We use 30-70% less energy than our competitors



7 x cleaner than existing methods of production.

USP

The only 'Ocean Derived' Hyaluronic Acid on the Market

Adds unique product claims



Drives premium pricing

Grow sales



12.1% CAGR 2023-2028₁

Route to Market

Leveraging existing Beauty Industry pull

GREEN CHEMICALS COMMERCIALISATION



INTERNAL PRODUCTION
Including CMO Partnerships



Partnerships & Distributors

CRODA

EVONIK
Leading Beyond Chemistry

Givaudan

End User



Unilever

L'ORÉAL

Industry
Pull

Designer Chemicals Direct Selling

Distribution

Surfachem

maesa
AETHIC




Traction

Technical & Commercial Traction

Multiple LOIs + MTAs

Winners of L'Oreal Sustainability Challenge 2025

TEA & Pilot Facility Design




Product Samples Created



Patent Filed




Scaling Up



Technology Platform Roadmap

Scaling from lab to industrial production in just 4 years




POC & MVP
(Lab Work)



Small Scale PBR
(Photobioreactor)

E2E
Demonstrator



Pilot
Scale
PBR


Pilot Scale
Plant



Integrated
Commercial Plant

Profitability by 2028

DBB Revenue and Profit Forecast



Team & Advisors

World class science, industry expertise and commercial acumen



Tim Corcoran
Chief Executive

Exited Founder & Business Developer



Dr. Lucia Burdisso
Chief Science

Molecular Biologist & Bioinformatician



Dr. Matt Proctor
Head of R&D

Molecular Biologist & Algae Biotechnology



Dr. Selva Turkolmez
Research Scientist

Molecular Biologist & Bioreactor Specialist



Manuel Rios
Chief Commercial

Beauty Industry & Sustainable Design



ADVISED BY EXPERTS FROM



THE UNIVERSITY of EDINBURGH


UEA University of East Anglia

Imperial College London



£4m Seed Round

Use of Funds - 24 Month Runway



0–6 Months	6–12 Months	12–18 Months	18–24 Months
Site secured & design finalised Hire key technical team	Pilot commissioned First sales of HA	Optimised productivity Optimised process	£1.75M/year HA output achieved Operational breakeven



£4m Seed Round Opening Q1 2026

Thank You!



Questions?
tim@deepbluebiotech.com



Contact Us
www.linkedin.com/company/deepbluebiotech/